$19.40
1.41% day before yesterday
Nasdaq, Nov 26, 10:00 pm CET
ISIN
US24823R1059
Symbol
DNLI

Denali Therapeutics Inc. Stock price

$19.40
+3.19 19.68% 1M
+5.98 44.56% 6M
-0.98 4.81% YTD
-5.28 21.39% 1Y
-9.43 32.71% 3Y
-41.22 68.00% 5Y
-2.05 9.56% 10Y
-2.05 9.56% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.27 1.41%
ISIN
US24823R1059
Symbol
DNLI
Industry

New AI Insights on Denali Therapeutics Inc. Insights AI Insights on Denali Therapeutics Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$2.8b
Enterprise Value
$2.0b
Net debt
positive
Cash
$848.2m
Shares outstanding
146.6m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 39,051.5
EV/Sales
- | 27,486.0
EV/FCF
negative
P/B
3.1
Financial Health
Equity Ratio
89.5%
Return on Equity
-34.4%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $72.9k
EBITDA
- | $-550.6m
EBIT
- | $-566.8m
Net Income
- | $-448.9m
Free Cash Flow
$-411.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -11.7%
EBIT
- | -12.9%
Net Income
- | -6.2%
Free Cash Flow
-9.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -755,675.2%
EBIT
-
Net
- | -616,088.2%
Free Cash Flow
-
More
EPS
-
FCF per Share
$-2.8
Short interest
10.7%
Employees
422
Rev per Employee
$0.0
Show more

Is Denali Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Denali Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Denali Therapeutics Inc. forecast:

24x Buy
96%
1x Hold
4%

Analyst Opinions

25 Analysts have issued a Denali Therapeutics Inc. forecast:

Buy
96%
Hold
4%

Financial data from Denali Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 116 116
16% 16%
-
- Research and Development Expense - -
-
-
-522 -522
7% 7%
-
- Depreciation and Amortization 12 12
41% 41%
-
EBIT (Operating Income) EBIT -534 -534
8% 8%
-
Net Profit -479 -479
14% 14%
-

In millions USD.

Don't miss a Thing! We will send you all news about Denali Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Denali Therapeutics Inc. Stock News

Neutral
Seeking Alpha
6 days ago
Denali Therapeutics Inc. ( DNLI ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM EST Company Participants Ryan Watts - Co-Founder, President, CEO & Director Alexander Schuth - Co-Founder, CFO, COO & Secretary Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Presentation Lin Tsai Jefferies LLC, Research Division Okay. We're going to get started with...
Neutral
GlobeNewsWire
22 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2025, and provided business highlights.
Neutral
GlobeNewsWire
about 2 months ago
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. The Prescri...
More Denali Therapeutics Inc. News

Company Profile

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Ryan Watts
Employees 422
Founded 2013
Website www.denalitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today